DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for hyper-IgM syndrome type 2 — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHyper-IgM syndrome type 2 maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hyper-igm syndrome type 2 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
activation induced cytidine deaminase (AICDA) — AICDA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1hdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5W1C · 3.18 Å · ligand 4-AMINO-1-BETA-D-RIBOFURANOSYL-2(1H)-PYRIMIDINONE (CTN). Experimental structure, not a prediction.
What the evidence adds up to
The 2002 review describes hyper-IgM syndrome as a primary immunodeficiency characterised by defects in the CD40 signalling pathway, including the CD40/CD40L interaction. The review states that molecular diagnosis will help provide the most appropriate treatment and prognosis, but it does not report any clinical trial results, survival data, or response rates for any drug.
A 2004 case report describes a patient with hyper-IgM syndrome who had skewed production of serum IgG subclasses and normal somatic hypermutation. The authors suggest this case may represent a subgroup of HIGM type 4. No drug treatment or outcome data are reported.
A 2024 case report describes an infant with hyper-IgM syndrome whose clinical presentation was dominated by persistent chronic neutropenia. The report states that the syndrome is caused by a defect in B lymphocytes and is characterised by normal or high serum IgM with low or zero IgG, IgA, and IgE. No drug, treatment, or outcome data are reported.
No clinical trial, no drug tested, no survival or response rate, and no evidence of efficacy for any intervention is provided in these abstracts. What is missing is any clinical trial testing a drug for hyper-IgM syndrome type 2, any patient stratification by genetic subtype, and any funding for such trials.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Allergy and Clinical Immunology · 2002 · 38 citations
Cross-talk between CD40 and CD40L: lessons from primary immune deficiencies
AbstractPURPOSE OF REVIEW: The purpose of this review is to provide an update of the molecular bases of CD40-mediated signalling and of the human immune defects associated with abnormalities of this activation pathway. RECENT FINDINGS: Over the last years considerable progress in the identification of intracellular molecules mediating CD40 signalling has been achieved. This review focuses on the recent work on the molecular mechanisms of CD40 signalling mediated by tumor necrosis factor receptor-associated factors, by transcription of the activation-induced cytidine deaminase gene and by activation of nuclear factor kappa B. Furthermore, the importance of CD40/CD40L interaction for the induction of adaptive immunity will be outlined in the context of primary immunodeficiencies due to defects of the genes involved in the CD40 signalling pathway, which are characterized by an immunological phenotype of hyper-IgM syndrome. SUMMARY: The critical role of CD40/CD40L interactions in the development of various disease states has been fully appreciated, and further understanding of the molecular events involved in CD40 signalling may allow the identifications of candidate genes for other hyper-IgM syndromes. Molecular diagnosis will help to provide the most appropriate treatment and prognosis.
Clinical and Vaccine Immunology · 2004 · 2 citations · open access
Biased Immunoglobulin G (IgG) Subclass Production in a Case of Hyper-IgM Syndrome
AbstractHyper-immunoglobulin M (IgM) syndrome (HIGM) is a rare heterogeneous primary immune deficiency. We describe a patient with HIGM characterized by skewed production of serum IgG subclasses and normal somatic hypermutation. This case may represent a subgroup of HIGM type 4 that is characterized by a biased switching to the V-region proximal constant regions.
International Journal of Advanced Research · 2024 · 0 citations · open access
CHRONIC NEUTROPENIA REVEALING HYPER IGM SYNDROME: A CASE REPORT
AbstractHyper IgM syndrome is a well-knownhereditaryimmunodeficiency, first describedin 1961. It iscaused by a defect in B lymphocytes, characterized by a normal or high serumlevel of IgM and a low or zerolevel of IgG, IgA, IgE resultingfrom a deficiency in isotype switching. Itsclinical manifestations are dominated by recurrent infections, especiallyrespiratory and digestive. The interest of this article is to illustrate a particular mode of revelation of hyper IgM syndromes through persistent chronicneutropenia in an infant.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
